Cardiovascular diseases: Lipid-lowering in CKD-at the SHARP end of the evidence?

Nature Reviews Nephrology

Volumn 7, Issue 11, 2011, Pages 609-611

  Palmer, Suetonia C ^a   Strippoli, Giovanni F M ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DEATH; DIALYSIS; DRUG ACTIVITY; DRUG EFFICACY; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL;

CLINICAL PROTOCOLS; FEMALE; HEMODIALYSIS, HOME; HUMANS; MALE; MONITORING, PHYSIOLOGIC; UREMIA;

EID: 80155214695     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.136     Document Type: Article

References (10)

1. Baigent, C. et al. for the Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
2. Baigent, C. et al. on behalf of the SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181-2192 (2011).
3. Chonchol, M., Cook, T., Kjekshus, J., Pedersen, T. R. & Lindenfeld, J. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am. J. Kidney Dis. 49, 373-382 (2007).
4. Kendrick, J. et al. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am. J. Kidney Dis. 55, 42-49 (2010).
5. Ridker, P. M., MacFadyen, J., Cressman, M. & Glynn, R. J. Efficacy of rosuvastatin among men and women with moderate chronic kidneydisease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J. Am. Coll. Cardiol. 55, 1266-1273 (2010).
6. Tonelli, M. et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110, 1557-1563 (2004).
7. Wanner, C. et al. for the German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248 (2005).
8. Fellström, B. C. et al. for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 360, 1395-1407 (2009).
9. Strippoli, G. F. & Craig, J. C. Sunset for statins after AURORA? N. Engl. J. Med. 360, 1455-1457 (2009).
10. Strippoli, G. F. et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336, 645-651 (2008).